TM editors’ note: This article discusses a penny stock and/or microcap. Such stocks are easily manipulated; do your own careful due diligence. Written by SmallCapPower.com The gold mining stocks on our list today all trade at large discounts to forward Price to Cash Flow per share multiples, as compared with their peer average of 5.7x….
Listen to the Podcast Audio: Click Here Mike Gleason: It is my privilege now to welcome in Greg Weldon, CEO and President of Weldon Financial. Greg has over three decades of market research and trading experiencing, specializing in the metals and commodity markets and even authored a book in 2006 titled, Gold Trading Boot Camp where…
The switch from central bank gold sales to purchases had a big impact on the gold market. Precious metals investors fail to realize that central banks sold a staggering amount of gold into the market up until 2009. It’s also quite interesting that central banks became net purchasers after the 2008 market meltdown. There’s been…
After years of monthly payroll reports padded with excessive minimum wage waiter, bartender, educator or retail worker jobs, the just released April jobs report, disappointing as it may have been on the top-line, showed surprising strength in most components even if some negative surprises were also present. Of note: the biggest jobs growth in April…
It was another volatile week on Wall Street as investors digested a slew of economic and earnings data. Apple was the big standout winner last week as the stock shot up to new highs after reporting earnings and legendary investor Warren Buffet announced he was increasing his position in the stock. In other news, the bulls…
A balanced jobs report on Friday spurred a rally to bring stocks back to about even for the week. Official unemployment dropped to 3.9%, but soft wage gains may encourage the Fed to pursue a slower path of interest rate hikes. Apple, the world’s most valuable public company, rose 13% for the week, driven by…
My guess is that a short-term uptrend has started, but I am not ready to make the call quite yet with a couple of themajor indexes still below their 50-day average. Much healthier new highs/ new lows in today’s market. New 52-week lows diminished to a harmless level, and new highs perked up. The ultra…
First-quarter results of pharma bigwigs like Pfizer PFE, Merck MRK and Allergan AGN stole the limelight this week. Other than that, Novartis NVS gained FDA approval for the second indication of its CAR-T therapy, Kymriah. While AbbVie ABBV submitted a regulatory application in the EU for its psoriasis candidate, risankizumab, Merck’s PD-L1 inhibitor, Keytruda gained FDA’s Priority Review status for yet another label expansion…
